Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area
暂无分享,去创建一个
James J. Davis | D. Boutz | M. Nguyen | S. W. Long | R. Olsen | J. Musser | J. McLellan | M. Shukla | M. Kumaraswami | J. Gollihar | Hung-Che Kuo | Kamyab Javanmardi | Chia-Wei Chou | I. Finkelstein | D. Bernard | P. Christensen | M. Saavedra | P. Yerramilli | L. Pruitt | S. Subedi | Heather Hendrickson | Ghazaleh Eskandari | Hoang A. T. Nguyen | J. Long | Jule Goike | P. Christensen | D. W. Bernard | Heather L Hendrickson | J. Long
[1] K. Katoh,et al. MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.
[2] Samir Bhatt,et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil , 2020, Science.
[3] R. Welsh,et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.
[4] Geoffrey J. Barton,et al. Jalview Version 2—a multiple sequence alignment editor and analysis workbench , 2009, Bioinform..
[5] J. Dye,et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.
[6] K. Yuen,et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 , 2020, Cell.
[7] Fangfang Xia,et al. Population Genomic Analysis of 1,777 Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae Isolates, Houston, Texas: Unexpected Abundance of Clonal Group 307 , 2017, mBio.
[8] Gaël Varoquaux,et al. Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..
[9] P. Horby,et al. A novel coronavirus outbreak of global health concern , 2020, The Lancet.
[10] A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD , 2020 .
[11] E. Decroly,et al. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites , 2020, Antiviral Research.
[12] Timothy B. Stockwell,et al. Haemagglutinin mutations and glycosylation changes shaped the 2012/13 influenza A(H3N2) epidemic, Houston, Texas. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[13] R. Owens,et al. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike , 2020, Cell Host & Microbe.
[14] Yan Zhang,et al. Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir , 2020, bioRxiv.
[15] Tianqi Chen,et al. XGBoost: A Scalable Tree Boosting System , 2016, KDD.
[16] Melis N. Anahtar,et al. Phylogenetic analysis of SARS-CoV-2 in the Boston area highlights the role of recurrent importation and superspreading events. , 2020, medRxiv.
[17] S. Lo,et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.
[18] J. Sodroski,et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike , 2020, Nature.
[19] Rebecca J. Loomis,et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.
[20] Joy Y. Feng,et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.
[21] S. Anzick,et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 , 2020, Nature.
[22] Erwan L'Her,et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[23] D. A. Jackson,et al. Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity , 2020, Cell.
[24] Young-Jun Park,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[25] Xiaotao Lu,et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease , 2018, mBio.
[26] R. Schwartz,et al. Characteristics and Outcomes of COVID-19 Patients During Initial Peak and Resurgence in the Houston Metropolitan Area. , 2020, JAMA.
[27] The COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic , 2020, European Journal of Human Genetics.
[28] The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic , 2020, European Journal of Human Genetics.
[29] S. Perlman,et al. Another Decade, Another Coronavirus , 2020, The New England journal of medicine.
[30] M. Nguyen,et al. Molecular Architecture of Early Dissemination and Evolution of the SARS-CoV-2 Virus in Metropolitan Houston, Texas , 2020, bioRxiv.
[31] O. Tsang,et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[32] Shaohua Zhao,et al. Using machine learning to predict antimicrobial minimum inhibitory concentrations and associated genomic features for nontyphoidal Salmonella , 2018, bioRxiv.
[33] H. Feldmann,et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection , 2020, Proceedings of the National Academy of Sciences.
[34] R. Haubrich,et al. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] R. Lorenzo-Redondo,et al. A Unique Clade of SARS-CoV-2 Viruses is Associated with Lower Viral Loads in Patient Upper Airways , 2020, medRxiv.
[36] H. Deng,et al. The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity and decreases neutralization sensitivity to individual convalescent sera , 2020 .
[37] Emily R. Davenport,et al. Integrated analysis of population genomics, transcriptomics and virulence provides novel insights into Streptococcus pyogenes pathogenesis , 2019, Nature Genetics.
[38] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[39] J. Erdmann,et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure , 2020, The New England journal of medicine.
[40] K. Allel,et al. Country-level factors associated with the early spread of COVID-19 cases at 5, 10 and 15 days since the onset , 2020, Global public health.
[41] Sarah K. Hilton,et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition , 2020, bioRxiv.
[42] Z. Rao,et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody , 2020, Science.
[43] Sarah K. Hilton,et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding , 2020, Cell.
[44] Yiwei Cao,et al. Developing a Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein Model in a Viral Membrane , 2020, The journal of physical chemistry. B.
[45] Nguyen H. Tran,et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.
[46] J. Mascola,et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.
[47] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[48] Trevor Bedford,et al. Cryptic transmission of SARS-CoV-2 in Washington state , 2020, Science.
[49] R. Bruno,et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[50] Larissa B. Thackray,et al. A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies , 2020, Cell.
[51] P. Sorger,et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques , 2020, Science.
[52] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[53] A. M. Leontovich,et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.
[54] S. W. Long,et al. Treatment of COVID-19 Patients with Convalescent Plasma , 2020, The American Journal of Pathology.
[55] Qiang Zhou,et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.
[56] S. Rawson,et al. Distinct conformational states of SARS-CoV-2 spike protein , 2020, Science.
[57] Edward C. Holmes,et al. Human Adaptation of Ebola Virus during the West African Outbreak , 2016, Cell.
[58] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[59] Charu C. Aggarwal,et al. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining , 2016, KDD.
[60] D. Lauffenburger,et al. Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[61] E. Holmes,et al. A new coronavirus associated with human respiratory disease in China , 2020, Nature.
[62] S. Rowland-Jones,et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.
[63] M. Farzan,et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity , 2020, bioRxiv.
[64] Lisa E. Gralinski,et al. Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.
[65] M. Nussenzweig,et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies , 2020, Cell.
[66] Kari Stefansson,et al. Spread of SARS-CoV-2 in the Icelandic Population , 2020, The New England journal of medicine.
[67] V. Munster,et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.
[68] G. Atwal,et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies , 2020, Science.
[69] Y. Hu,et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial , 2020, The Lancet.
[70] B. Grimberg,et al. The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera , 2020, bioRxiv.
[71] D. Burton,et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.
[72] M. V. van Breemen,et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.
[73] Jason J. Lavinder,et al. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus neutralization. , 2020, The Journal of clinical investigation.
[74] G. Atwal,et al. REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters , 2020, bioRxiv.
[75] Vineet D. Menachery,et al. Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility , 2020, Nature.
[76] Larissa B. Thackray,et al. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection , 2020, The Journal of Immunology.
[77] Ilya J. Finkelstein,et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.
[78] Nathan R Kern,et al. Developing a Fully-glycosylated Full-length SARS-CoV-2 Spike Protein Model in a Viral Membrane , 2020, bioRxiv.
[79] Paramvir S. Dehal,et al. FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments , 2010, PloS one.
[80] M. Nussenzweig,et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.
[81] Kristie B. Hadden,et al. 2020 , 2020, Journal of Surgical Orthopaedic Advances.
[82] I. Wilson,et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.
[83] Gintaras Deikus,et al. Introductions and early spread of SARS-CoV-2 in the New York City area , 2020, Science.
[84] Pardis C Sabeti,et al. Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant , 2020, bioRxiv.
[85] R. Olsen,et al. Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality , 2020, The American Journal of Pathology.
[86] Linqi Zhang,et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.
[87] C. Rice,et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.
[88] H. Deng,et al. D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity , 2020, bioRxiv.
[89] S. Becker,et al. Functional Characterization of Adaptive Mutations during the West African Ebola Virus Outbreak , 2016, Journal of Virology.
[90] James J. Davis,et al. Developing an in silico minimum inhibitory concentration panel test for Klebsiella pneumoniae , 2017, Scientific Reports.
[91] L. Guddat,et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus , 2020, Science.
[92] Frank Grosveld,et al. A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.
[93] Pardis C Sabeti,et al. SARS-CoV-2 Spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding domain , 2020, bioRxiv.
[94] Pardis C. Sabeti,et al. Ebola Virus Glycoprotein with Increased Infectivity Dominated the 2013–2016 Epidemic , 2016, Cell.
[95] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.